Hippo信号通路与原发性肝癌发生发展及治疗研究进展

Hippo信号转导通路首先在果蝇体内被发现,是一条高度保守、抑制细胞生长的信号通路.其核心分子包括Hpo、Sav、Wts、Mats及下游效应因子YAP/TAZ,在人类中有对应的同源类似物,分别为哺乳动物STE20蛋白样激酶家族1/2(mammalian STE20 protein-like kinase 1/2,MST1/2)、萨尔瓦多家族1(salvatore family 1,SAVl)、大肿瘤抑制基因1/2激酶(large tumor suppressor gene 1/2 kinase,LATS1/2)和MOB激酶激活物1A/1B(mob kinase activator 1A/1B,MOB1A/1B).当该通路失活时,可促进癌细胞存活、增殖、侵袭性迁移和转移,该过程可见于肝癌、肺癌、结直肠癌、乳腺癌、胰腺癌、以及黑素瘤和胶质瘤等多种癌症中,可导致化疗、放疗或免疫治疗耐药的发生.因此,本文旨在综述Hippo信号通路对肝癌发生发展及治疗的影响,以期为肝癌新的靶向疗法提供参考.

Role of Hippo signaling pathway in occurrence,development,and treatment of primary hepatocellular carcinoma

The Hippo signal transduction pathway,first discovered in drosophila,is a highly conserved signaling pathway that inhibits cell growth.Its core molecules include Hpo,Sav,Wts,Mats,and downstream effector factor YAP/TAZ.Corresponding homologous analogs in humans are STE20 protein-like kinase 1/2,Salvatore family 1,large tumor suppressor gene 1/2 kinase,and MOB kinase activator 1A/1B.Inactivation of this pathway promotes the survival,proliferation,invasive migration,and metastasis of cancer cells.This process can be seen in liver cancer,lung cancer,colorectal cancer,breast cancer,pancreatic cancer,melanoma,glioma,and other cancers,which can lead to the occurrence of resistance to chemotherapy,radiotherapy,or immunotherapy.This paper aims to review the role of the Hippo signaling pathway in the occurrence,development,and treatment of liver cancer,in order to provide reference for new targeted therapies for liver cancer.